Introduction

Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in the bone marrow, accounting for 1% of all cancers and approximately 10% of all hematological malignancies. The median age at MM diagnosis is 67–70 years and only 3% of the patients are diagnosed before 40 years of age. Moreover, MM is approximately 1.5 times more prevalent in men compared with women. Therefore, the simultaneous occurrence of pregnancy and MM is rare. The first case describing MM diagnosis during a pregnancy was published in 1965. Between 1965 and 2020, 44 cases of MM, diagnosed around or during pregnancy, were reported in the literature. The most common early symptoms of MM are bone pain (58% of patients), fatigue (32%), and recurrent infections. End-target organ damage according to the CRAB criteria includes hypercalcemia (28%), renal failure (48%), anemia (73%), and lytic bone lesions (20–25%). Some of these symptoms may also be attributed to the normal course of pregnancy. The challenge of diagnosing MM during pregnancy is demonstrated in the case presented here. The patient had signs that were primarily ascribed to her pregnancy and therefore the investigation was initially directed toward pregnancy-related disorders, such as iron deficiency, preeclampsia, or primary kidney disorder. The patient provided written consent for publishing this case report. The case report followed the CARE guidelines.

Case report

A 40-year-old previously healthy woman, gravida 12, para 10, was admitted for an investigation due to elevated blood pressure (180/115 mmHg) and acute renal failure (serum creatinine 1.5 mg/dL, previously normal) at gestational week 16 of index pregnancy. The patient was asymptomatic. Although she had a history of gestational hypertension during her three most recent pregnancies, she was not followed and was never treated for it. Notable laboratory findings included normocytic anemia, hemoglobin 9.4 g/dL, platelets 272 K/µL, and white blood cells 7.69 K/µL. There was no evidence of iron deficiency (iron 70 µg/dL, transferrin 277 mg/dL, ferritin 151.2 mg/mL). Serum albumin, lactate dehydrogenase, and
electrolytes were within normal range. Total urine protein collected over 24 h was 1.3 g.

Therapy with labetalol 200 mg was started, and the patient was followed at the pregnancy high-risk unit in collaboration with the nephrology unit. During this period, blood pressure remained high and stable and renal function deteriorated to 2.06 mg/dL during week 22.

A kidney core needle biopsy, performed at week 23 + 4, showed 25 normocellular glomeruli without signs of active glomerular disease. No evidence of glomerular capillary wall thickening was observed. The interstitium showed focally prominent infiltration by leukocytes with multiple eosinophils and lymphocytes. Masson trichrome stain highlighted about 20% fibrosis. The tubules demonstrated multiple areas of tubulitis while the vessels showed no significant changes.

The morphological picture was compatible with tubulointerstitial disease with a prominent acute inflammatory component.

Immunostaining for cytomegalovirus, herpes simplex virus, and polyomavirus was negative. Congo red staining was negative for amyloid material. Immunofluorescence staining for IgA, IgG, IgM, C3, C4, C1q, lambda, fibrinogen, and albumin deposits was also negative. Scanning electron microscopy showed two normocellular glomeruli with prominent thinning of the glomerular basement membrane, and tubules with signs of epithelial cell damage.

The ultrastructural findings were consistent with thin membrane disease associated with tubular damage.

At 25 weeks of pregnancy, serum electrophoresis and immunofixation showed an unquantifiable IgG kappa monoclonal band. Serum IgG was 582 mg/dL (normal 700–1600), IgA 43 mg/dL (normal 70–500), and IgM 22 mg/dL (normal 40–280). Serum free light chain assay demonstrated high levels of kappa light chain 3120 mg/L (normal 3.3–19.4), preserved lambda 7.3 mg/L (normal 5.7–26.3), and a significantly skewed κ/λ ratio of 427.7 (0.26–1.65). Repeated 24-h urine protein collection demonstrated 2.21 g of urine protein, of which 1.91 g were Bence Jones protein. Bone marrow (BM) biopsy revealed infiltration by 70–80% kappa light chain-restricted plasma cells.

Congo red stain was negative for amyloid. Fluorescent in situ hybridization (FISH) testing of plasma cells showed del13q and t(11;14). Whole-body magnetic resonance imaging (MRI) revealed lack of homogeneity along the spine vertebrae with multiple ‘salt and pepper’ foci. Focal lesions, 8 mm in diameter, were observed in the D8 vertebra and in the left pedicle of the D3 vertebra. Focal lesions, 17 mm in diameter, were observed in the left ilium wing and several bilateral tiny lesions were noted in the iliac bones. The BM along the thighs was inhomogeneous with no evidence for focal lesions (Figure 1).

The findings obtained from the MRI scan, BM biopsy, and the monoclonal proteins observed in the blood and urine all led to the diagnosis of oligosecretory IgG kappa MM, Revised International Staging System (R-ISS) 2, with predominantly kappa light chain secretory disease.

Upon the diagnosis of active MM with anemia, renal and skeletal injuries, there was a clear indication for treatment initiation. Considering that the patient did not wish to terminate the pregnancy, together with the advanced gestational age, therapy with high-dose dexamethasone (HDD) 40 mg/d was initiated.

HDD was administered on days 1–4, 9–12, and 17–20. After one treatment cycle there was no response: serum-free kappa remained stable at 2760 mg/L and serum creatinine was unchanged. Therefore, weekly cyclophosphamide (CTX) 500 mg/m² was added to HDD on gestational week 27, resulting in partial response with a reduction in serum-free kappa to as low as 1540 mg/L. Creatinine improved to 1.21 mg/dL. The patient signed an informed consent for this treatment.

Therapy was continued during gestational weeks 27–34 with no further reductions in serum-free kappa light chain and in serum creatinine. Fetal development continued uneventfully, and fetal growth was appropriate for its gestational age.

On gestational week 35, increased creatinine level (1.27 mg/dL) and blood pressure (140/90 mmHg) were observed.

Due to the bony lesions in the pelvis observed by MRI, which increased the concern for a vaginal delivery, an elective caesarian section was performed on gestational week 36. A healthy female
baby, weighing 1940 g, was delivered with an Apgar score of 9 and 10 at 1 and 5 min, respectively.

A day after the delivery, treatment with bortezomib, lenalidomide, and dexamethasone was started. Five 28-day cycles were given resulting in very good partial response, with normalization of κ/λ ratio at the fourth cycle. Creatinine remained stable at 1.3 mg/dL. The patient proceeded with high-dose melphalan (200 mg/m²) followed by autologous stem cell transplantation (ASCT) performed 8 months from diagnosis.

BM biopsy at day 87 post-ASCT was normocellular for age with polyclonal plasma cells comprising up to 5% of the BM cell population. The patient achieved stringent complete response (sCR) 3 months post-ASCT, and lenalidomide maintenance therapy was started and continues to date with stable sCR.

Discussion
The incidence of MM during pregnancy is uncommon. To date, 45 cases (including the present case) of MM, diagnosed around or during pregnancy, have been reported in the literature (Tables 1 and 2). These cases included patients aged 21–43 years diagnosed before conception, during pregnancy, and up to 3 months after delivery. Eight patients were diagnosed before they had conceived: six of them had active MM when they conceived, one had a known monoclonal gammopathy of undetermined significance (MGUS) about 6 years before pregnancy, stable MGUS/smoldering MM during pregnancy and progressive active MM in the postpartum period. Two patients were in remission but the disease had relapsed during the pregnancy. Thirty-three patients were diagnosed during pregnancy: seven during the first trimester, 15 (including the present case) during the second trimester, and 11 during the third trimester. Five patients were diagnosed in the postpartum period. FISH and cytogenetic analysis were reported in a minority of patients, and no published data were available for analysis.

As summarized in Table 2, all five patients with an active disease were treated with an anti-myeloma agent before pregnancy, four of them were treated with these agents during the first trimester until the pregnancy was confirmed. Sixteen patients received treatment for multiple myeloma during their pregnancy: seven with steroids only and the remaining nine patients with various therapies. Twelve patients were not treated during their pregnancy, most of them due to their request not to be treated while pregnant. Thirty-two of 45 patients were treated with anti-myeloma therapy after delivery or pregnancy termination.

Forty-one women gave birth to 42 healthy babies, including a pair of twins. One patient had progressive disease and died after delivery. One newborn had an Apgar score of 5, which was followed by an uncomplicated neonatal course, and another had seizures at birth that were related to difficulties with calcium regulation, but was healthy at
Table 1. Summary of case reports on multiple myeloma in pregnancy (including the present report).

| Reference          | Symptoms                                                                 | Age at diagnosis (years) | GA at diagnosis | MM subtype | Durie & Salmon | ISS | Treatment                                                                 | GA at delivery | Fetal/neonatal status |
|--------------------|--------------------------------------------------------------------------|--------------------------|-----------------|------------|----------------|-----|---------------------------------------------------------------------------|----------------|-----------------------|
| Giordano et al.    | Bone pain                                                               | 40                       | Second trimester| NR         | III            | NR  | –                                                                         | CTX            | Unknown               |
| Kosova and Schwartz | Bone pain in lower back and hips                                       | 35                       | Before conception| NR         | III            | NR  | RT + urethane                                                            | 9 months       | Healthy               |
| Rosner et al.      | Bone pain, headaches                                                    | 42                       | Before conception| NR         | IIA            | NR  | Urethane                                                                | 9 months       | Healthy               |
| Talerman et al.    | Jaundice, anemia                                                        | 39                       | Third trimester  | NR         | IIA            | NR  | MP, oxymetholone; CTX                                                   | None           | Healthy               |
| Lergier et al.     | Generalized bone pain                                                  | 21                       | Before conception| IgG        | III            | NR  | MP; chlorambucil, prednisone; melphalan                                  | None           | Healthy               |
| Harster and Krause | Lethargy, hypercalcaemia, anemia                                        | 29                       | Postpartum      | NR         | III            | NR  | –                                                                         | None           | Healthy               |
| Caudle et al.      | Bone pain                                                               | 30                       | Postpartum      | IgGκ        | III            | NR  | –                                                                         | None           | Healthy               |
| Malee et al.       | Anemia, bone pain, right optic neuropathy, proximal lower extremity weakness, decreased response to pinprick beginning at thoracic level 4 | 32                       | Postpartum      | IgAκ        | IIA            | NR  | –                                                                         | None           | Healthy               |
| Pajor et al.       | Refractory anemia                                                      | 27                       | 16 weeks (second trimester) | IgGλ        | IIA            | NR  | –                                                                         | None           | Healthy               |
| Sakata et al.      | Anemia                                                                  | 38                       | Before conception| Light λ chains | IIB            | NR  | Vincristine, doxorubicin, dexamethasone, IFN α until 7 weeks gestation | None           | Healthy               |
| Maglione et al.    | Admitted for risk of miscarriage                                       | 34                       | 6 weeks (first trimester) | Light λ chains | IIA            | I   | –                                                                         | None           | Healthy               |

(Continued)
| Reference          | Symptoms                                                                 | Age at diagnosis (years) | GA at diagnosis       | MM subtype | Durie & Salmon | ISS | Treatment Before pregnancy | During pregnancy | Postpartum | GA at delivery | Fetal/neonatal status |
|--------------------|---------------------------------------------------------------------------|--------------------------|-----------------------|------------|----------------|-----|-----------------------------|-----------------|------------|-----------------|----------------------|
| 13 Forthman et al. | Bone pain, anemia                                                        | 41                       | 28 weeks (third trimester) | Light λ chains | IIIB          | NR  | –                           | None            | HDM with peripheral ASCT | 34 Healthy, except for seizures at birth that were related to difficulties with calcium regulation |
| 14 Malik et al.    | Excessive vomiting, light headedness, lethargy                            | 34                       | 15 weeks (second trimester) | IgG λ       | IIIB          | NR  | –                           | None            | VAD; external beam RT; CTX, thalidomide, dexamethasone | – Pregnancy was terminated at 19 weeks |
| 15 Lee et al.      | Diagnosed with monoclonal gammopathy of undetermined significance (MGUS) 5 years prior to conception. Postpartum: Increased lethargy, reduced appetite, nausea and vomiting, weight loss and back pain, renal failure. | 32                       | Postpartum IgG λ       | IIIB        | NR  | –                           | –               | –          | Healthy         |
| 16 Zun and Choi    | Back pain                                                                | 32                       | 31 weeks/third trimester | IgG λ       | IIIB          | II  | First line: VAD; second line: VTD | –               | 32 weeks Healthy |
| 17 Quinn et al.    | Back pain, urinary retention, bilateral lower limb weakness               | 39                       | 32 weeks/third trimester | IgG λ       | IIIB          | I   | First line: ID; second line: ESHAP followed by high-dose therapy with PBSC rescue; third line: VD | –               | 32 weeks Healthy |
| 18 Dabrowska et al.| Hypertension, anemia, proteinuria                                        | 42                       | 28 weeks (third trimester) | IgA κ       | II            | I   | –                           | –               | Chemotherapy; ASCT | 35 weeks Healthy twins |
| 19 Wilmott et al.  | Bone pain, anemia, thrombocytopenia                                      | 33                       | 15 weeks (second trimester) | Light chain only plasma cell myeloma | NR | I   | –                           | Dexamethasone   | CTD followed by HDM and PBSC rescue | 33 weeks Healthy |
| 20 Rodriguez et al.| Asthenia, hyperemesis, anemia, bone pain                                 | 31                       | 18 weeks (second trimester) | IgA λ       | III           | NR  | –                           | –               | Vincristine, doxorubicin, dexamethasone followed by IFN α | – Pregnancy was terminated |

Table 1. (Continued)
| Reference       | Symptoms                                                                 | Age at diagnosis (years) | GA at diagnosis  | MM subtype | Durie & Salmon | ISS | Treatment Before pregnancy | During pregnancy | Postpartum | GA at delivery | Fetal/neonatal status |
|----------------|--------------------------------------------------------------------------|--------------------------|------------------|------------|----------------|-----|--------------------------|-----------------|------------|----------------|-----------------------|
| 21 Kasenda et al.² | Lower back pain, anemia                                                  | 34                       | 23 weeks (second trimester) | Light κ chains | IIA            | I   | Prednisolone             | VCD; followed by IVE mobilization and tandem PBSC transplantation after HDM | 32 weeks | Healthy |
| 22 Aviles and Neri² | NR                                                                      | 32                       | First trimester  | NR         | NR            | NR  | CTX, MP, vincristine; MP  | NR              | 36         | Healthy |
| 23 NR            | Second trimester                                                         | 37                       | NR               | NR         | NR            | NR  | CTX, MP, vincristine, dexamethasone; MP | NR              | 38         | Healthy |
| 24 NR            | First trimester                                                         | 24                       | NR               | NR         | NR            | NR  | CTX, MP, vincristine, IFNα; MP | NR              | 33         | Healthy |
| 25 NR            | First trimester                                                         | 35                       | NR               | NR         | NR            | NR  | DHI MP ⁶                   | NR              | 34         | Healthy |
| 26 NR            | Second trimester                                                        | 39                       | NR               | NR         | NR            | NR  | DHI ⁶                   | NR              | 38         | Healthy |
| 27 NR            | Severe anemia, renal insufficiency, fracture of the femur and vertebral collapse | 32                       | Third trimester  | NR         | NR            | NR  | CTX, MP, vincristine ⁶     | NR              | 39         | Healthy |
| 28 Borja de Mozota et al.¹⁷ | Asymptomatic proteinuria                                                | 33                       | 12 weeks (first trimester) | IgG κ        | NR            | NR  | None                     | VCD followed by HDM, double ASCT, lenalidomide maintenance treatment | 34         | Healthy |
| 29 Brisou et al.¹⁵ | Relapse during pregnancy: Low back pain, anemia                        | 26 (initial diagnosis – 12 years prior to conception) | Initial diagnosis 12 years prior to conception. Relapse at 7 months of pregnancy (third trimester) | Light κ chains | IIA            | NR  | First line: VAD (vincristine, doxorubicin, dexamethasone, pamidronate, radiotherapy. Second line: VAD followed by high-dose cyclophosphamide, double autologous stem cell transplant after high-dose melphalan | None            | 37         | Healthy |
| 30 Bouzguenda et al.¹⁶ | Bilateral breast lumps                                                  | 39                       | 26 weeks (second trimester) | IgG λ        | IIA            | II  | Dexamethasone            | TD, external beam RT | 34         | Healthy |
| 31 Smith et al.¹¹ | Proteinuria, anemia                                                     | 34                       | 24 weeks (second trimester) | Light κ chains | IIA            | I   | Dexamethasone            | VD, HDM, ASCT    | 35         | Healthy |
| 32 Back pain, leg weakness, decreased sensation and difficulty voiding urine | 38                       | 32 (third trimester) | IgG λ        | IIA            | I   | –                        | –               | 32         | Healthy |
| Reference | Symptoms | Age at diagnosis (years) | GA at diagnosis | MM subtype | Durie & Salmon | ISS | Treatment Before pregnancy | During pregnancy | Postpartum | GA at delivery | Fetal/ neonatal status |
|-----------|----------|------------------------|-----------------|------------|----------------|-----|---------------------------|-----------------|------------|----------------|----------------------|
| 33        | Cytopenia, hypercalcemia | 33 | 14 weeks (second trimester) | Light λ chains | IIA | I |  | Dexamethasone |  |  | 33 | Healthy |
| 34 Khot et al. | Persistent hemorrhage after spontaneous abortion | 30 | Postpartum | IgG λ | NR | I |  |  |  | Vincristine, doxorubicin, dexamethasone; HPC harvest after CTX and rh-SCSF mobilization; autologous HPC transplant after HDM; intravenous bisphosphonate therapy | NR | Spontaneous abortion |
| 35        | NR | 32 | 14 weeks (second trimester) | Light κ chains | III | I |  |  |  | VAD, RT; vincristine, liposomal doxorubicin, dexamethasone; high-dose CTX, dexamethasone, HDM conditioned autologous HPC transplant; MUC-1 loaded dendritic cell injections, investigational therapy with a VEGF inhibitor, pazopanib, bortezomib dexamethasone; bortezomib, romidepsin, dexamethasone; thalidomide; VCD | NR | Pregnancy termination |
| 36 McIntosh et al. | Epigastric pain, nausea, vomiting, rib and back pain, pancreatitis | 22 | 32 weeks (third trimester) | Light κ chain | IIB | I |  |  |  | NR | 32 | Apgar 5, followed by uncomplicated neonatal course |
| 37 Cabanas-Perianes et al. | Anemia | 37 | 27 weeks (third trimester) | IgG λ | IIA | II | None |  |  | VRD | Healthy |
### Table 1. (Continued)

| Reference       | Symptoms                                                                 | Age at diagnosis (years) | GA at diagnosis | MM subtype | Durie & Salmon | ISS | Treatment Before pregnancy | During pregnancy | Postpartum | GA at delivery | Fetal/ neonatal status |
|-----------------|---------------------------------------------------------------------------|--------------------------|-----------------|------------|----------------|-----|----------------------------|------------------|------------|------------------|-------------------------|
| Jurczyszyn et al.⁶ | Rib fractures, anemia, hypercalcemia associated with acute renal failure | 43                       | 28 weeks (third semester) | Light \(\kappa\) chain | IIB            | III | high-dose methylprednisolone | VD, bortezomib, pomalidomide | 30         | Healthy          |                         |
| Rib fractures, anemia, hypercalcemia associated with acute renal failure | 43                       | 28 weeks (third semester) | Light \(\kappa\) chain | IIB            | III | high-dose methylprednisolone | VD, bortezomib, pomalidomide | 30         | Healthy          |                         |
| 39               | Back pain                                                                 | 39                       | 31 weeks (third trimester) | \(\text{IgA}\) \(\lambda\) | IIIA           | I   | Dexamethasone               | VD; autologous PBSC transplant; RD; VRD; pomalidomide, dexamethasone | 36         | Healthy          |                         |
| 40               | Mild cytopenias                                                           | 34                       | Before conception   | Smoldering myeloma; \(\text{IgG}\) \(\lambda\) | IA             | I   | None                        | Yes [treatment details were not specified] | NR         | Healthy          |                         |
| 41               | NR                                                                        | NR                       | First trimester    | Solitary plasmacytoma | IA             | II  | None                        | Yes [treatment details were not specified] | NR         | Healthy          |                         |
| 42               | NR                                                                        | NR                       | First trimester    | \(\text{IgG}\) \(\lambda\) | IIIA           | I   | None                        | Yes [treatment details were not specified] | NR         | Healthy          |                         |
| 43               | Abdominal distention, lower extremity pitting edema, proteinuria          | 34                       | 20 weeks (second trimester) | Light chain deposition disease | NR             | NR | –                          | VTD              | 24 weeks  | Stillborn        |                         |
| 44               | Progressive weakness and backache                                         | 29                       | Before conception   | \(\text{IgG}\) \(\kappa\) | NR             | NR | Vincristine, doxorubicin, dexamethasone; TD | VCD; ASCT | 37 weeks  | Healthy          |                         |
| 45               | Present case                                                              | 40                       | 16 weeks (second trimester) | \(\text{IgG}\) \(\kappa\) | –              | Revised ISS II | – | HDD; CTX and HD | VCD; ASCT | 36 weeks  | Healthy          |                         |

ASCT, autologous stem cell transplantation; CMOP, cyclophosphamide, melphalan, vincristine, prednisone; CTD, cyclophosphamide, thalidomide, dexamethasone; CTX, cyclophosphamide; DHI, double hemibody irradiation; ESHAP, etoposide, cisplatin, cytarabine, methylprednisolone; GA, gestational age; HDD, high-dose dexamethasone; HDM, high-dose melphalan; HPC, hematopoietic progenitor cell; ICD, idarubicin, cyclophosphamide, dexamethasone; ID, idarubicin, dexamethasone; IFN, interferon alpha; ISS, International Staging System; IVE, ifosfamide, epirubicin, etoposide; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MP, melphalan, prednisone; MUC-1, Mucin 1, cell surface associated; NR, not reported; PBSC, peripheral blood stem cells; RD, lenalidomide, dexamethasone; rh-GCSF, recombinant human granulocyte colony-stimulating factor; RT, radiotherapy; TD, thalidomide, dexamethasone; VAD, bortezomib, doxorubicin, dexamethasone; VCD, bortezomib, cyclophosphamide, dexamethasone; VD, bortezomib, dexamethasone; VEGF, vascular endothelial growth factor; VRD, bortezomib, lenalidomide, dexamethasone; VTD, bortezomib, thalidomide, dexamethasone.

Chemotherapy was stopped 3–4 weeks before delivery to avoid hematological toxicity in the newborn.
Table 2. Summary of the demographic and clinical characteristics of cases of multiple myeloma in pregnancy (including the present report).

| Parameter | Case reports
|-----------|------------------|
|           | \(N = 45\)       |
| Age, years | 21–43            |
| Diagnosis of multiple myeloma |     |
| Before conception | 8 (5 with active disease; one had smouldering myeloma; 2 experienced a relapse during pregnancy) |
| During pregnancy | 32 |
| First trimester | 7 |
| Second trimester | 15 |
| Third trimester | 11 |
| Postpartum | 5 |
| After delivery of a healthy baby | 4 |
| After spontaneous abortion | 1 |
| Multiple myeloma subtype |     |
| IgG \(\lambda\) | 10 |
| IgA \(\lambda\) | 2 |
| IgD \(\lambda\) | 1 |
| Light \(\lambda\) chains | 4 |
| Light \(\kappa\) chains | 5 |
| IgG \(\kappa\) | 5 |
| IgA \(\kappa\) | 2 |
| IgG | 1 |
| Plasma cell myeloma | 1 |
| Solitary plasmacytoma | 1 |
| Light chain deposition disease of \(\lambda\) type | 1 |
| Not reported | 11 |
| Durie-Salmon Classification |     |
| IA | 2 |
| II | 1 |
| IIA | 5 |
| IIIB | 1 |
| III | 7 |
| IIIA | 10 |
| IIIB | 7 |
| Not evaluated | 11 |
| International Staging System (ISS) |     |
| I | 14 |
| II | 4 |
| III | 1 |
| Not reported | 25 |
| Revised ISS score |     |
| II | 1 |
| Treatment |     |
| Before pregnancy | 5 |
| During pregnancy | 20 |
| Dexamethasone | 5 |
| Cyclophosphamide | 2 |
| Urethane | 2 (one until GA 6 weeks, one until pregnancy confirmation) |
| Prednisolone | 1 |
| Methylprednisolone | 1 |
| Dexamethasone, cyclophosphamide | 1 |
| CMOP, MP | 1 |
| CMOP, doxorubicin, MP | 1 |
| CMOP, Interferon \(\alpha\), MP | 1 |
| Double hemibody irradiation, MP | 1 |
| Double hemibody irradiation | 1 |
| CMOP | 1 |
| Interferon \(\alpha\) | 1 (until GA 7 weeks) |
| Thalidomide, dexamethasone | 1 (until GA 12 weeks) |
| Not treated during the pregnancy | 12 |
| Postpartum | 33 |
| Neonatal status |     |
| Healthy | 41 |
| Pregnancy termination | 3 |
| Spontaneous abortion | 1 |
| Stillbirth | 1 |
| Unknown status | 1 |
| CMOP, cyclophosphamide, melphalan, vincristine, prednisone; GA, gestational age; ISS, International Staging System; MP, melphalan, prednisone. |
follow-up.23 Three pregnancies were terminated.8,13,22 One woman had a spontaneous abortion, after which MM was diagnosed; the women gave birth to a healthy baby 5 years later, despite a relapse of the disease during the pregnancy.13

Due to the low prevalence of MM in young adults, the initial investigation of the underlying causes of the patient’s symptoms – hypertension and acute renal failure – was directed toward pregnancy-related disorders, such as iron deficiency, preeclampsia, or primary kidney disorder, delaying the initial diagnosis. Once diagnosis was determined, treatment was initiated in order to delay disease progression and further damage to target organs while maintaining the safety of the fetus. The therapy regimen included CTX and HDD which enabled the completion of the pregnancy and the delivery of a healthy baby.

Treating physicians should be aware of potential effects of MM therapies on the fetus and pregnancy outcomes. Table 3 summarizes the limited evidence on the safety of the major classes of MM therapies during pregnancy. Most anti-MM agents have shown embryo lethality or teratogenicity when given during pregnancy in animal studies. Despite the widespread use of corticosteroids in MM protocols,37 high-dose corticosteroids confer a slightly higher risk for fetal malformations in the first trimester, and a higher risk for obstetric complications in the second or third trimesters.38–41 Prednisolone is the preferred steroid as it is metabolized by the placenta with only 10% of maternal dose reaching the fetus.42 In the case described here, the patient received HDD and CTX. CTX was also administered to two other pregnant patients – one in the second trimester and one in the third – but did not affect

Table 3. Classification of multiple myeloma therapy by fetal risks.

| Drug             | Mechanism of action                                                                 | Effect on fetus                                                                                                                                                                                                 | FDA pregnancy categories | Australian categorization system |
|------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------------------------|
| Corticosteroids  | Broad anti-inflammatory and immunosuppressive activity.37                          | A marginally increased risk of major malformations after first-trimester exposure to corticosteroids. Increase by an order of 3.4-fold the risk of oral cleft,41 preterm rupture of the fetal membranes,39 effect on fetal hypothalamic-pituitary-adrenal axis development,38 preterm birth, maternal diabetes. | A                        | A                                |
| Cyclophosphamide | Alkylating agent. The phosphoramide mustard metabolite forms irreversible DNA cross-links between and within DNA strands at guanine N-7 positions, leading to cell apoptosis.44 | Cyclophosphamide embryopathy, including growth restriction, ear and facial abnormalities, absence of digits and hypoplastic limbs.45 Low-dose intravenous CTX therapy may not be hazardous to the fetus during late pregnancy.43 | D                        | D                                |
| Melphalan        | Alkylating agent. Nitrogen mustard analog. Targets actively dividing cells.46       | Evidence of embryo lethality and teratogenicity when given during pregnancy in animal studies. Effects in humans are unknown.46                                                          | D                        | D                                |

(Continued)
Table 3. (Continued)

| Drug | Mechanism of action | Effect on fetus | FDA pregnancy categories<sup>a</sup> | Australian categorization system<sup>b</sup> |
|------|---------------------|-----------------|--------------------------------------|------------------------------------------|
| **Immuno-modulatory drugs** | | | | |
| Thalidomide and derivatives: lenalidomide, pomalidomide | Anti-proliferative and pro-apoptotic effects on malignant cells, immune regulatory function, interruption of tumor microenvironment interactions. | Severe fetal defects and embryofetal deaths.<sup>48</sup> | Not assigned | X |
| **Proteosome inhibitors** | | | | |
| Bortezomib | Inhibition of protein degradation through the ubiquitin-proteasome system thereby leading to accumulation of misfolded or unfolded proteins in plasma cells. The accumulated proteins produce activation of pro- and anti-proliferative signals, interfere with the cell cycle, and activate apoptotic pathways that lead to cell death.<sup>49,50</sup> | Embryo-fetal lethality in rabbits. Significant post-implantation loss and a reduced number of live fetuses. Live fetuses had significantly lower fetal weight.<sup>51</sup> No controlled data regarding the use of bortezomib in human pregnancies. | D | C |
| Carfilzomib | Embryo-fetal toxicity in rabbits. No teratogenicity in pregnant rats when the drug was administered during the organogenesis period (Note: carfilzomib exposure in animals was below the exposure achieved in humans).<sup>51</sup> | Not assigned | C |
| Ixazomib | Ixazomib caused embryo-fetal toxicity only at maternally toxic doses and at exposures that were slightly higher than those observed in patients receiving the recommended dose. In pregnant rabbits, increased fetal external abnormalities in the tail were observed at doses $\geq 1.0$ mg/kg, and skeletal variations/abnormalities were observed at doses $\geq 0.3$ mg/kg.<sup>52</sup> | Not assigned | C |
| **Monoclonal antibodies** | | | | |
| Daratumumab | A humanized Ig G1-kappa mAb that targets CD38, a 46-kDa type II transmembrane glycoprotein broadly expressed on plasma cells.<sup>53</sup> Binding of daratumumab to CD38 induces myeloma cells death by several mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis.<sup>54</sup> | IgG1 monoclonal antibodies cross the placenta after the first trimester of pregnancy and may cause fetal myeloid or lymphoid-cell depletion and decreased bone density. | Not assigned | C |
## Table 3. (Continued)

| Drug          | Mechanism of action                                                                 | Effect on fetus                                                                 | FDA pregnancy categories<sup>a</sup> | Australian categorization system<sup>b</sup> |
|---------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|
| Isatuximab    | An IgG1 monoclonal antibody that binds selectively to a specific epitope on the CD38 receptor. This binding can target tumor cells through a combination of mechanisms, including ADCC, ADCP, CDC, and immune cell depletion/inhibition of T regulatory cells.<sup>55</sup> | Animal reproduction studies have not been conducted with this drug.             | Not assigned                          | C                                           |
| Elotuzumab    | Elotuzumab is a monoclonal antibody that primarily acts via ADCC and also by directly activating natural killer cells to kill myeloma cells.<sup>56</sup> | No data regarding use in pregnant animals or humans.                             | Not assigned                          | C                                           |

ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity; CTX, cyclophosphamide; FDA, Food and Drug Administration.
<sup>a</sup>Chemical Hazards Emergency Medical Management. FDA Pregnancy Categories. US Department of Health and Human Services. Available from: https://chem.nlm.nih.gov/pregnancycategories.htm.
<sup>b</sup>Australian categorisation system for prescribing medicines in pregnancy. Australian Government Department of Health. Therapeutic Goods Administration. Available from: https://www.tga.gov.au/australian-categorisation-system-prescribing-medicines-pregnancy.

the development of the fetus.<sup>4,29</sup> Low-dose CTX administered to a patient with Burkitt’s lymphoma during the third trimester showed good response with delivery of a normal baby, suggesting that low-dose intravenous CTX therapy may not be hazardous to the fetus during late pregnancy.<sup>43</sup>

In conclusion, despite the rarity of concurrent MM and pregnancy, this possibility should be considered in patients with signs and symptoms that may be attributed to MM so as not to delay the diagnosis and decision about pregnancy continuation and initiation of appropriate, safe, and efficient therapy.

**Author contributions**

**Hila Magen:** Data curation; Writing – original draft; Writing – review & editing.

**Michal J. Simchen:** Data curation; Writing – review & editing.

**Shira Erman:** Data curation.

**Abraham Avigdor:** Writing – review & editing.

**Conflict of interest statement**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Hila Magen  [ORCID](https://orcid.org/0000-0002-3990-394X)

**References**

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014; 15: e538–548.

2. Kasenda B, Ruckert A, Farthmann J, et al. Management of multiple myeloma in pregnancy: strategies for a rare challenge. *Clin Lymphoma Myeloma Leuk* 2011; 11: 190–197.

3. Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. *JAMA Oncol* 2018; 4: 1221–1227.

4. Giordano C. [Multiple myeloma and pregnancy (1st case in the world literature)]. *Matern Infanc* 1965; 24: 158–184.

5. Kim MJ, Kim JH, Kim IY, et al. Light chain deposition disease associated with multiple
myeloma developing in late pregnancy. Iran J Kidney Dis 2018; 12: 132–134.

6. Jurczyszyn A, Olszewska-Szopa M, Vesole AS, et al. Multiple myeloma in pregnancy – a review of the literature and a case series. Clin Lymphoma Myeloma Leuk 2016; 16: e39–e45.

7. Garg A, Aggarwal M and Kashyap R. Pregnancy and its successful outcome in a patient with multiple myeloma. J Obstet Gynaecol India 2021; 71: 78–81.

8. Rodríguez LGR, Llanes OA, Padrón CH, et al. The multiple myeloma and the pregnancy: first case report in Cuba. Rev Cuba Hematol Immunol Hemoter 2010; 26: 70–75.

9. Aviles A and Neri N. Multiple myeloma and pregnancy. Am J Hematol 2011; 86: 81–82.

10. Willmott F, Agarwal N, Heath M, et al. Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep 2010; 2010: bcr0420102901.

11. Smith D, Stevens J, Quinn J, et al. Myeloma presenting during pregnancy. Hematol Oncol 2014; 32: 52–55.

12. McIntosh J, Lauer J, Gunatilake R, et al. Multiple myeloma presenting as hypercalcemic pancreatitis during pregnancy. Obstet Gynecol 2014; 124(2 Pt 2, Suppl. 1): 461–463.

13. Khot AS, Prince HM, Harrison SJ, et al. Myeloma and pregnancy: strange bedfellows? Leuk Lymphoma 2014; 55: 866–869.

14. Cabanas-Perianes V, Macizo M, Salido E, et al. Management multiple myeloma during pregnancy: a case report and review. Hematol Oncol 2016; 34: 108–114.

15. Brisou G, Bouafia-Sauvy F, Karlin L, et al. Pregnancy and multiple myeloma are not antinomic. Leuk Lymphoma 2013; 54: 2738–2741.

16. Bouzguenda R, Khanfir A, Toumi N, et al. Multiple myeloma presenting as bilateral breast lumps in pregnant woman. Int J Hematol 2013; 98: 487–490.

17. Borja de Mozota D, Kadhel P, Dermeche S, et al. Multiple myeloma and pregnancy: a case report and literature review. Arch Gynecol Obstet 2011; 284: 945–950.

18. Dabrowska DM, Gore C, Griffiths S, et al. Anaesthetic management of a pregnant patient with multiple myeloma. Int J Obstet Anesth 2010; 19: 336–339.

19. Maglione A, Di Giorgio G, Petruzelli F, et al. Multiple myeloma diagnosed during early pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol 2003; 111: 214–215.

20. Quinn J, Rabin N, Rodriguez-Justo M, et al. Multiple myeloma presenting with spinal cord compression during pregnancy. Ann Hematol 2009; 88: 181–182.

21. Lee JC, Francis RS, Smith S, et al. Renal failure complicating myeloma in pregnancy. Nephrol Dial Transplant 2007; 22: 3652–3655.

22. Malik S, Oliver R and Odejinmi F. A rare association with hyperemesis: pregnancy and multiple myeloma. J Obstet Gynaecol 2006; 26: 693–695.

23. Forthman CL, Ponce BA and Mankin HJ. Multiple myeloma with a pathologic fracture during pregnancy. A case report. J Bone Joint Surg Am 2004; 86: 1284–1288.

24. Zun KH and Choi HM. Multiple myeloma presenting as vertebral compression during pregnancy. Int J Gynaecol Obstet 2008; 100: 89–90.

25. Sakata H, Karamitsos J, Kundaria B, et al. Case report of interferon alfa therapy for multiple myeloma during pregnancy. Am J Obstet Gynecol 1995; 172: 217–219.

26. Pajor A, Kelemen E, Mohos Z, et al. Multiple myeloma in pregnancy. Int J Gynaecol Obstet 1991; 35: 341–342.

27. Malee MP. Multiple myeloma in pregnancy: a case report. Obstet Gynecol 1990; 75: 513–515.

28. Harster GA and Krause JR. Multiple myeloma in two young postpartum women. Arch Pathol Lab Med 1987; 111: 38–42.

29. Lergier JE, Jimenez E, Maldonado N, et al. Normal pregnancy in multiple myeloma treated with cyclophosphamide. Cancer 1974; 34: 1018–1022.

30. Talerman A, Serjeant GR and Milner PF. Normal pregnancy in a patient with multiple myeloma and sickle cell anaemia. West Indian Med J 1971; 20: 97–100.

31. Rosner F, Soong BC, Krim M, et al. Normal pregnancy in multiple myeloma treated with cyclophosphamide. Cancer 1974; 34: 1018–1022.

32. Kosova LA and Schwartz SO. Multiple myeloma and normal pregnancy. Report of a case. Blood 1966; 28: 102–111.
33. Caudle MR, Dodd S and Solomon A. Multiple myeloma in pregnancy: a case report. *Obstet Gynecol* 1990; 75: 516–518.

34. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. *Haematologica* 2015; 100: 107–113.

35. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc* 2003; 78: 21–33.

36. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. *BMJ Case Rep* 2013; 2013: bcr2013201554.

37. Burwick N and Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. *Ann Hematol* 2019; 98: 19–28.

38. Braun T, Challis JR, Newnham JP, et al. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. *Endocr Rev* 2013; 34: 885–916.

39. Guller S, Kong L, Wozniak R, et al. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. *J Clin Endocrinol Metab* 1995; 80: 2244–2250.

40. Lockwood CJ, Radunovic N, Nastic D, et al. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. *J Perinat Med* 1996; 24: 243–251.

41. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 2000; 62: 385–392.

42. Paizis K. Immunomodulatory drugs in pregnancy and lactation. *Aust Prescr* 2019; 42: 97–101.

43. Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. *J Natl Med Assoc* 1979; 71: 165–166.

44. Hall AG and Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. *Blood Rev* 1992; 6: 163–173.

45. Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? *Am J Med Genet* 1999; 86: 237–241.

46. Choy M. Pharmaceutical approval update. *PT* 2016; 41: 288–333.

47. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. *Leukemia* 2010; 24: 22–32.

48. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. *Birth Defects Res C Embryo Today* 2015; 105: 140–156.

49. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. *Leuk Res* 2014; 38: 1–9.

50. Chhabra S. Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. *Pharmaceuticals* 2017; 10: 40.

51. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. *Clin Cancer Res* 2004; 10: 3954–3964.

52. Tzogani K, Flores B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. *ESMO Open* 2019; 4: e000570.

53. Nishida H and Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. *J Oncol* 2019; 2019: 6084012.

54. Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol* 2016; 9: 51.

55. Wudhikarn K, Wills B and Lesokhin AM. Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action. *Best Pract Res Clin Haematol* 2020; 33: 101143.

56. Ritchie D and Colonna M. Mechanisms of action and clinical development of elotuzumab. *Clin Transl Sci* 2018; 11: 261–266.